84006-10-0

Basic information

• Product Name: 2-(Chloromethyl)-3,5-dimethyl-4-methoxypyridine
• Synonyms: 2-(CHLOROMETHYL)-4-METHOXY-3, 5-DIMETHYLPYRIDINE;2-CHLOROMETHYL-3,5-DIMETHYL-4-METHOXYPYRIDINE;2-Chloromethyl-3-,5-Dimethyl-4-;Pyridine, 2-(chloromethyl)-4-methoxy-3,5-dimethyl- (9CI);2-Chloromethyl-3,5-dimethyl-4-methoxypyridine ,98%;2-(Chloromethyl)-4-methoxy-3,5-lutidine;2-Chloromethyl-3,5-dimethyl-4-methoxypyr;2-(Chloromethyl)-3,5-dimethyl-4-methoxypyridine###2-CHLOROMETHYL-3,5-DIMETHYL-4-METHOXYPYRIDINE HCL 84006-10-0
• CAS NO: 84006-10-0
• Molecular Formula: C₉H₁₂ClNO
• Molecular Weight: 185.65
• Product Categories: HALOMETYL;Pyridine;Pyridines;pyridine series;Heterocycle-Pyridine series
• Mol File: 84006-10-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 272.2 °C at 760 mmHg
• Flash Point: 118.4 °C
• Appearance: /
• Density: 1.112 g/cm³
• Vapor Pressure: 0.0103mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 5.56±0.40(Predicted)
• CAS DataBase Reference: 2-(Chloromethyl)-3,5-dimethyl-4-methoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Chloromethyl)-3,5-dimethyl-4-methoxypyridine(84006-10-0)
• EPA Substance Registry System: 2-(Chloromethyl)-3,5-dimethyl-4-methoxypyridine(84006-10-0)

Safety Data

• Statements: R34:Causes burns.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36/37/39:Wear suitabl
• HazardClass: IRRITANT
• Hazardous Substances Data: 84006-10-0(Hazardous Substances Data)

Usage

Uses

2-(Chloromethyl)-4-methoxy-3,5-dimethylpyridine is an intermediate in the synthesis of Omeprazole (O635000), an antiulcer agent.

InChI:InChI=1/C9H12ClNO.ClH/c1-6-5-11-8(4-10)7(2)9(6)12-3;/h5H,4H2,1-3H3;1H

Upstream product

• 86604-80-0 4-methoxy-2,3,5-trimethylpyridine 1-oxide 
• 109371-19-9 4-methoxy-2,3,5-trimethylpyridine 
• 91219-90-8 (4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl acetate 
• 86604-78-6 (4-methoxy-3,5-dimethylpyridin-2-yl)methanol 

Downstream Products

• 122307-85-1 2-(4-Methoxy-3,5-dimethyl-pyridin-2-ylmethylsulfanyl)-6-phenyl-3H-thieno[3,4-d]imidazole 
• 122307-88-4 2-(4-Methoxy-3,5-dimethyl-pyridin-2-ylmethylsulfanyl)-6-(4-methoxy-phenyl)-3H-thieno[3,4-d]imidazole 
• 848694-53-1 4-chloro-7-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-5-phenylaminomethyl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamine 
• 848694-51-9 4-chloro-5-[(dibenzylamino)-methyl]-7-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamine 
• 1247013-52-0 C₄₉H₄₁N₇OS 
• 73590-58-6 omeprazole 
• 73590-60-0 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole 
• 86604-75-3 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride 

Relevant articles and documents

Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction

Genetic rearrangements of the mixed lineage leukemia (MLL) leading to oncogenic MLL-fusion proteins (MLL-FPs). MLL-FPs occur in about 10% of acute leukemias and are associated with dismal prognosis and treatment outcomes which emphasized the need for new therapeutic strategies. In present study, by a cell-based screening in-house compound collection, we disclosed that Rabeprazole specially inhibited the proliferation of leukemia cells harboring MLL-FPs with little toxicity to non-MLL cells. Mechanism study showed Rabeprazole down-regulated the transcription of MLL-FPs related Hox and Meis1 genes and effectively inhibited MLL1 H3K4 methyltransferase (HMT) activity in MV4-11 cells bearing MLL-AF4 fusion protein. Displacement of MLL1 probe from WDR5 protein suggested that Rabeprazole may inhibit MLL1 HMT activity through disturbing MLL1-WDR5 protein-protein interaction. Moreover, other proton pump inhibitors (PPIs) also indicated the inhibition activity of MLL1-WDR5. Preliminary SARs showed the structural characteristics of PPIs were also essential for the activities of MLL1-WDR5 inhibition. Our results indicated the drug reposition of PPIs for MLL-rearranged leukemias and provided new insight for further optimization of targeting MLL1 methyltransferase activity, the MLL1-WDR5 interaction or WDR5.

METHOD FOR THE SYNTHESIS OF A BENZIMIDAZOLE COMPOUND

A process for the manufacture of omeprazole or esomeprazole from pyrmethyl alcohol via pyrmethyl chloride and pyrmetazole characterized in that the whole reaction sequence is carried out without any isolation or purification of intermediates. Further, the reaction is carried out in a solvent system common for the whole reaction sequence and inert to the reactants formed during the process and used in the process and comprises a water immiscible organic solvent and a specified amount of water.

2--1H-thienoimidazoles. A Novel Class of Gastric H+/K+-ATPase Inhibitors

2-thienoimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase.The isomers of the two possible thienoimidazole series were found to be potent inhibitors of gastric acid secretion in vitro and in vivo.Structure-activity relationships indicate that especially lipophilic alkoxy, benzyloxy, and phenoxy substituents with additional electron-demanding properties in the 4-position of the pyridine moiety combined with an unsubstituted thienoimidazole lead to highly active compounds with a favorable chemical stability.Various substitution patterns in the thienoimidazole moiety result in lower biological activity.The heptafluorobutyloxy derivative saviprazole (HOE 731, 5d) was selected for further development and is currently undergoing clinical evaluation.Comprehensive pharmacological studies indicate a pharmacodynamic profile different to omeprazole, the first H+/K+-ATPase blocker introduced on the market.